Researchers at the National Institutes of Health (NIH) have determined that dermatitis resulting from topical steroid withdrawal (TSW) is distinct from eczema and is caused by an excess… read more.
Galderma announced that the European Commission has approved Nemluvio (nemolizumab) for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now approved for… read more.
Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. The safety… read more.
Kyowa Kirin Co., Ltd announced that results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe… read more.
Johnson & Johnson announced the submission of two supplemental Biologics License Applications (sBLAs) to the FDA seeking approval of Tremfya (guselkumab) for the treatment of children 6 years… read more.
Galderma announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing… read more.
Painful skin and trouble sleeping are among the problems reported when tapering cortisone cream for atopic eczema. This has been shown by a study headed by the University… read more.
For the first two to three weeks of their lives, infants have to undergo screening for neonatal jaundice (NNJ). It typically involves frequent clinic visits, which is not… read more.
NICE (UK): 1.1 Tebentafusp is recommended, within its marketing authorisation, for treating HLA‑A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company provides… read more.
Tapinarof 1% cream (Vtama) has been approved by the Food and Drug Administration (FDA) for the treatment of atopic dermatitis (AD, eczema) in adults and children of two… read more.
Organon announced that the FDA has approved Vtama (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis (AD)… read more.
Galderma announced that the FDA has approved Nemluvio (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS)… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
